Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

StockNews.com lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Other analysts have also ...

Q4 2024 Earnings Call Transcript February 13, 2025 Bio-Rad Laboratories, Inc. beats earnings expectations. Reported EPS is $2 ...

Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...

Bio-Rad has entered a binding offer to purchase all equity interests in French biotech Stilla Technologies. According to ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

Bio-Rad projects 2025 currency-neutral revenue growth of 1.5%-3.5%, excluding contributions from acquisitions. Diagnostics revenue is expected to grow between 2%-3%, while Life Science revenue is ...

HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations, sending shares down 4% in after-hours trading Thursday.

Reports Q4 revenue $667.5M, consensus $679.75M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, commented: “Bio-Rad demonstrated ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to ...

Sumitomo Mitsui Trust Group Inc. lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing ...